A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib

J Thorac Oncol. 2019 Nov;14(11):e257-e259. doi: 10.1016/j.jtho.2019.06.028.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anaplastic Lymphoma Kinase / antagonists & inhibitors
  • Anaplastic Lymphoma Kinase / genetics*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Drug Resistance, Neoplasm
  • Humans
  • Lactams, Macrocyclic / pharmacology*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Mutation*
  • Organophosphorus Compounds / pharmacology*
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / pharmacology*

Substances

  • Lactams, Macrocyclic
  • Organophosphorus Compounds
  • Protein Kinase Inhibitors
  • Pyrimidines
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • brigatinib
  • lorlatinib